The North America Wearable Injectors Market would witness market growth of 8.9% CAGR during the forecast period (2022-2028).
The device is intended to be prefilled with medicine and kept cold. The device container is approximately 76mm (3.0 inches) long in its current 3ml configuration. The needle enters the skin with the push of a button once the device is attached to the user's body. It should be spun 90 degrees anti-clockwise in the patient's hand. During the injection procedure, the device makes no noise. The needle retracts after completion, and the user can remove and dispose it. These devices significantly streamline the injection process, due to which, the demand for them is rapidly increasing among consumers.
Beyond the device's simplicity, wearable injectable devices provide a slew of advantages to users and medication companies. The device's capabilities enable it to give bigger dosages along with higher viscosities, and in some circumstances both. This is done while minimizing the patient's discomfort from higher doses and, in many situations, reducing the total number of injections required. These items can enable medication delivery in the patient's home rather than a clinical setting in cases where pharmaceuticals are supplied intravenously over extended periods of time, such as in the diagnosis of cancer or auto-immune illnesses. Keeping unnecessary time in the hospital or clinical setting to a minimum lowers the risk of hospital-acquired infections (HAIs).
Chronic diseases are long-term illnesses that develop gradually over time, typically worsening in severity, and can be regulated but not cured. Cardiovascular disorders (stroke and heart disease), cancer, arthritis, diabetes, back pain, asthma, and persistent depression are among them. Chronic diseases can drastically impair daily physical and mental processes, as well as limit one's capacity to undertake daily activities. Chronic diseases have surpassed infectious diseases as the primary cause of mortality and disability around the world. According to the Ministry of Health, noncommunicable illnesses currently account for 59% of the world's 57 million annual deaths and 46% of the global disease burden. The situation is very similar in Ontario. Heart disease was the biggest cause of death in the province in 2003, with myocardial infarction being the most common type of heart illness. Cancer, stroke, as well as a chronic obstructive pulmonary disease, were the next leading causes of death.
The US market dominated the North America Wearable Injectors Market by Country 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3,597.8 Million by 2028. The Canada market estimated to grow at a CAGR of 11.4% during (2022 - 2028). Additionally, The Mexico market would showcase a CAGR of 10.4% during (2022 - 2028).
Based on Therapy, the market is segmented into Diabetes, Cardiovascular disease, Immuno-oncology, and Others. Based on End User, the market is segmented into Hospitals & Clinics and Home healthcare setting. Based on Type, the market is segmented into On-body Injector and Off-body Injector. Based on Technology, the market is segmented into Spring Based, Motor Based, Rotary pump, Expanding battery, and others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global Wearable Injectors Market is Estimated to reach $12.9 Billion by 2028, at a CAGR of 9.2%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Insulet Corporation, United Therapeutics Corporation, ATS Automation Tooling Systems, Inc., Ypsomed AG, Amgen, Inc., West Pharmaceutical Services, Inc., Zealand Pharma A/S (Valeritas, Inc.), Medtronic PLC, CeQur SA, and Subcuject ApS.
By Therapy
By End User
By Type
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
